Skip to content
Loop Biz – Lifestyle
Author:
BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting
May 21, 2026
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid
May 20, 2026
BlossomHill Therapeutics to Present Initial Clinical Dose Escalation Data from the Phase 1/1b Trial of BH-30236 in Patients with R/R AML or HR-MDS at EHA2026
May 12, 2026
BlossomHill Therapeutics Presents First Preclinical Data from New Pan-KRAS Inhibitor Program Built on a Novel Chemical Scaffold During Mini Symposium at AACR 2026
April 22, 2026
BlossomHill Therapeutics Unveils New Pan-KRAS Inhibitor Programs and Announces Upcoming Presentations at AACR Annual Meeting 2026
March 17, 2026